These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy. Meng C; Su H; Shu M; Shen F; Lu Y; Wu S; Su Z; Yu M; Yang D Cell Death Dis; 2024 Sep; 15(9):683. PubMed ID: 39294131 [TBL] [Abstract][Full Text] [Related]
84. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Ni YG; Berenji K; Wang N; Oh M; Sachan N; Dey A; Cheng J; Lu G; Morris DJ; Castrillon DH; Gerard RD; Rothermel BA; Hill JA Circulation; 2006 Sep; 114(11):1159-68. PubMed ID: 16952979 [TBL] [Abstract][Full Text] [Related]
85. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. Koitabashi N; Aiba T; Hesketh GG; Rowell J; Zhang M; Takimoto E; Tomaselli GF; Kass DA J Mol Cell Cardiol; 2010 Apr; 48(4):713-24. PubMed ID: 19961855 [TBL] [Abstract][Full Text] [Related]
86. Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon Regulatory Factor-2 Binding Protein 2). Fang J; Li T; Zhu X; Deng KQ; Ji YX; Fang C; Zhang XJ; Guo JH; Zhang P; Li H; Wei X Hypertension; 2017 Sep; 70(3):515-523. PubMed ID: 28716987 [TBL] [Abstract][Full Text] [Related]
87. Cdc42 is an antihypertrophic molecular switch in the mouse heart. Maillet M; Lynch JM; Sanna B; York AJ; Zheng Y; Molkentin JD J Clin Invest; 2009 Oct; 119(10):3079-88. PubMed ID: 19741299 [TBL] [Abstract][Full Text] [Related]
88. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769 [TBL] [Abstract][Full Text] [Related]
89. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Liu W; Zi M; Tsui H; Chowdhury SK; Zeef L; Meng QJ; Travis M; Prehar S; Berry A; Hanley NA; Neyses L; Xiao RP; Oceandy D; Ke Y; Solaro RJ; Cartwright EJ; Lei M; Wang X Circ Heart Fail; 2013 Jul; 6(4):833-44. PubMed ID: 23753531 [TBL] [Abstract][Full Text] [Related]
90. Opposing roles of FoxP1 and Nfat3 in transcriptional control of cardiomyocyte hypertrophy. Bai S; Kerppola TK Mol Cell Biol; 2011 Jul; 31(14):3068-80. PubMed ID: 21606195 [TBL] [Abstract][Full Text] [Related]
91. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model. van Oort RJ; Respress JL; Li N; Reynolds C; De Almeida AC; Skapura DG; De Windt LJ; Wehrens XH Hypertension; 2010 Apr; 55(4):932-8. PubMed ID: 20157052 [TBL] [Abstract][Full Text] [Related]
92. Perturbation of the interactions of calmodulin with GRK5 using a natural product chemical probe. Beyett TS; Fraley AE; Labudde E; Patra D; Coleman RC; Eguchi A; Glukhova A; Chen Q; Williams RM; Koch WJ; Sherman DH; Tesmer JJG Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15895-15900. PubMed ID: 31337679 [TBL] [Abstract][Full Text] [Related]
93. Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodeling. Xie S; Chen M; Fang W; Liu S; Wu Q; Liu C; Xing Y; Shi W; Xu M; Zhang M; Chen S; Zeng X; Wang S; Deng W; Tang Q EBioMedicine; 2022 Dec; 86():104359. PubMed ID: 36395739 [TBL] [Abstract][Full Text] [Related]
94. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Kimura TE; Jin J; Zi M; Prehar S; Liu W; Oceandy D; Abe J; Neyses L; Weston AH; Cartwright EJ; Wang X Circ Res; 2010 Mar; 106(5):961-70. PubMed ID: 20075332 [TBL] [Abstract][Full Text] [Related]
95. G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Johnson LR; Scott MG; Pitcher JA Mol Cell Biol; 2004 Dec; 24(23):10169-79. PubMed ID: 15542828 [TBL] [Abstract][Full Text] [Related]
96. Annexin A7 deficiency potentiates cardiac NFAT activity promoting hypertrophic signaling. Voelkl J; Alesutan I; Pakladok T; Viereck R; Feger M; Mia S; Schönberger T; Noegel AA; Gawaz M; Lang F Biochem Biophys Res Commun; 2014 Feb; 445(1):244-9. PubMed ID: 24508799 [TBL] [Abstract][Full Text] [Related]
97. Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling. Huang Y; Wu D; Zhang X; Jiang M; Hu C; Lin J; Tang J; Wu L Gene; 2014 Feb; 536(2):225-31. PubMed ID: 24378234 [TBL] [Abstract][Full Text] [Related]
98. MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Ge Y; Pan S; Guan D; Yin H; Fan Y; Liu J; Zhang S; Zhang H; Feng L; Wang Y; Xu R; Yin JQ Biochim Biophys Acta; 2013 Jan; 1832(1):1-10. PubMed ID: 23000971 [TBL] [Abstract][Full Text] [Related]
99. Connective tissue growth factor/CCN2 attenuates β-adrenergic receptor responsiveness and cardiotoxicity by induction of G protein-coupled receptor kinase-5 in cardiomyocytes. Gravning J; Ahmed MS; Qvigstad E; Krobert K; Edvardsen T; Moe IT; Hagelin EM; Sagave J; Valen G; Levy FO; Osnes JB; Skomedal T; Attramadal H Mol Pharmacol; 2013 Sep; 84(3):372-83. PubMed ID: 23778361 [TBL] [Abstract][Full Text] [Related]
100. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy. Huang S; Zou X; Zhu JN; Fu YH; Lin QX; Liang YY; Deng CY; Kuang SJ; Zhang MZ; Liao YL; Zheng XL; Yu XY; Shan ZX J Cell Mol Med; 2015 Mar; 19(3):608-19. PubMed ID: 25583328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]